Our findings may offer novel therapeutic insights into targeting ASM-ceramide-MR redox signaling or TXNIP to suppress the activation of endothelial NLRP3 inflammasomes, thereby preventing and treating vasculopathy associated with hypercholesterolemia. This evidence concerns the gene NLRP3 and vascular disorder.